IROC yields 5.07% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 10
Combined, IROC + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IROC + JNJ for your $10,000?
Invesco Rochester High Yield Municipal ETF (fund) is an actively managed exchange-traded fund (ETF) that seeks current income exempt from federal income tax. The fund seeks to achieve its investment objective by investing, under normal market conditions, at least 75% of its net assets in higher yielding municipal securities, specifically medium-and-lower grade municipal securities. The fund will normally maintain a weighted average portfolio duration of less than 7.5 years.Effective February 24, 2025, The Fund will invest at least 75% of its total assets in low-to medium-quality municipal securities. The Fund’s name will change to “Invesco Rochester High Yield Municipal ETF.” As a result of this change, the Fund will also change its ticker to “IROC.”Effective July 1, 2025 through June 30, 2026, Invesco Capital Management LLC (the “Adviser”) will voluntarily waive 100% of its management fee, 0.39%, for the Fund. The Net Expense Ratio for the Fund through June 30, 2026 is 0.00%.
Full IROC Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.